GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Antibody-Drug Conjugates Show Unique Advantage in Breast …
Nov 19, 2024 · Erika P. Hamilton, MD, director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, discusses antibody-drug conjugates (ADCs) in multiple types of breast cancer, and when to use these drugs in sequence.
FDA Approves Daratumumab Plus VRd in Newly Diagnosed …
Jul 31, 2024 · About the Phase 3 PERSEUS Study. To be eligible for participation in the PERSEUS study, patients had to be between the ages of 18 and 70 years and have newly diagnosed, transplant-eligible multiple myeloma and an ECOG performance status of 2 or less. 2. In the control arm, patients received 1.3 mg/m 2 of subcutaneous bortezomib on days 1, 4, 8, and 11, plus 25 mg of oral lenalidomide on days 1 ...
Advancements in Follicular Lymphoma Treatment With Targeted …
Nov 14, 2024 · The treatment options for follicular lymphoma (FL) are rapidly advancing, driven by the development of new, promising therapies. At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory FL.
Tremelimumab Plus Durvalumab Turns Heads With Updated Five …
Sep 16, 2024 · Updated 5-year data from the phase 3 HIMALAYA study (NCT03298451) showed that the combination of single tremelimumab (Imjudo) with a regular interval of durvalumab (Imfinzi) elicited improved overall survival (OS) across multiple evaluations, including disease control and depth of response, in patients with unresectable hepatocellular carcinoma (uHCC).
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
Jan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers Symposium.
NCCN Updates Breast Cancer Guidelines to Include Goserelin
Feb 8, 2024 · Goserelin (Zoladex) has been included in the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel at 2 dosing schedules, 3.6 mg every 4 weeks and 10.8 mg every 12 weeks, as a method for ovarian function suppression in Version 1.2024 of the breast cancer guidelines. 1 As an injectable luteinizing hormone-releasing hormone agonist, goserelin is used to treat patients with prostate ...
Pembrolizumab Plus Lenvatinib Shows ‘Encouraging’ DOR in …
Jan 19, 2024 · The addition of pembrolizumab (Keytruda) to lenvatinib (Lenvima), compared with lenvatinib plus placebo, led to consistent overall (OS) and progression-free survival (PFS) outcomes previously found among patients with advanced hepatocellular carcinoma (HCC) treated in the phase 3 LEAP-002 trial (NCT03713593). 1 However, 35% of responders to the frontline regimen experienced an extended ...
Targeted Therapies in Oncology - Targeted Oncology
Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA news, and more. Click Here to Subscribe